View clinical trials related to Vaginal Diseases.
Filter by:This is an open user study to evaluate D005 vagnial mousse with regards to user-friendliness, and measure time from start of treatment to symptom relief and measure the clarity of instructional material. The study will be conducted at seven sites in Sweden, the study population will consist of up to 100 female subjects.
Efficacy and safety of two new formulations compared to Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections was evaluated in this randomized, three-arms, multicentral study.
This study evaluates the efficacy and safety of a new hyaluronic acid-based vaginal moisturizer gel to ease symptoms of vaginal dryness compared to a commonly used marketed vaginal moisturizer (Cumluade Hidratante Interno®).
Evaluate the improvement of regulation of skin and blood index composition after consumption of Omegia® Softgel
Characterization of the vaginal microbiota of women under fertile age and study of correlations with gynecological disorders
Primary Objective The primary objective is to explore the feasibility of collecting a vaginal sample using the OriCol™ Sampling Device. Secondary Objectives The study has secondary objectives to assess: 1. Acceptability of the sampling technique to both patient and clinician 2. To understand the balloon volume (maximum 80ml) required for effective intra-vaginal sampling. 3. Participant feedback during and after the test for using the OriCol™ Sampling Device using a Visual Analogue Scale 4. Patient discrete choice of Oricol™ versus speculum examination.
The goal of this clinical trial is to learn about the vaginal microbiome in premenopausal women with recurrent bacterial vaginosis (BV). The main questions it aims to answer are: - Does using a specific vaginal care system reduce recurrence of BV? - How does using this vaginal care system change the vaginal microbiome and pH over time? Participants will: - Have their vaginal microbiome and pH tested in several ways at three timepoints: the start of the study, 12 weeks later, and 24 weeks after the start of the study - Answer questionnaires about vulvovaginal symptoms at each of these three timepoints - Use a specific vaginal care system at home for 24 weeks, consisting of an intimate wash, a vaginal moisturizing gel, and a vaginal probiotic suppository, if assigned to the intervention group Researchers will compare the group using the vaginal care system with a control group that does not use the system to see if using the system reduces risk of BV recurrence or changes the vaginal microbiome, pH, or symptoms.
In a population of women with heightened vulvovaginal sensitivity and recurrent bacterial vaginosis (BV), the use of the Flourish HEC Vaginal Care System is being tested for prevention of BV recurrence over six months of use.
Open, single arm trial that intends to confirm the safety and efficacy of Multi-Gyn ActiGel Plus for treatment of Bacterial Vaginosis. Adult women will be diagnosed by the gynaecologist based on the Amsel criteria at day 0. They will use the product for 7 days and will come to the practice at day 21. The primary endpoint is the clinical cure rate of Bacterial Vaginosis at 3 weeks after start of treatment.
The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.